Tang Capital Group Holds 2.8% of Tarsus Stock
Tarsus Pharmaceuticals, Inc. received an amended Schedule 13G/A showing that investment entities associated with Kevin Tang collectively beneficially own 1,188,624 shares of Tarsus common stock.
Rhea-AI Filing Summary
Tarsus Pharmaceuticals, Inc. received an amended Schedule 13G/A showing that investment entities associated with Kevin Tang collectively beneficially own 1,188,624 shares of Tarsus common stock. This represents 2.80% of the company’s outstanding common shares as of October 29, 2025.
The shares are held with shared voting and dispositive power through Tang Capital Management, LLC and its affiliated funds, including Tang Capital Partners, Tang Capital Partners International, Tang Capital Partners III, Inc., and Tang Capital Partners IV, Inc. The filing notes that the securities are not held for the purpose of changing or influencing control of Tarsus.
Positive
- None.
Negative
- None.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What ownership stake in Tarsus Pharmaceuticals (TARS) is reported in this Schedule 13G/A?
Who are the reporting persons in the Tarsus Pharmaceuticals (TARS) Schedule 13G/A?
What does the certification in the Tarsus (TARS) Schedule 13G/A say about control intentions?
AI-generated analysis. How Rhea-AI works. Not financial advice.